Embecta

Embecta is a global medical device company exclusively dedicated to diabetes care, formed via a 2022 spin-off from Becton, Dickinson and Company (BD). Its mission is to leverage a 100-year heritage in injection devices to enhance the daily lives of over 30 million people with diabetes worldwide through its core products: insulin pen needles and syringes. The company's strategy is to focus its R&D and commercial resources entirely on advancing mechanical insulin delivery, improving patient comfort, and expanding access in global markets. As a newly independent public entity, Embecta aims to drive growth by deepening its patient-centric innovation and operational execution.

A mechanical device platform centered on precision-engineered, single-use injection devices for subcutaneous insulin delivery, including a comprehensive range of insulin pen needles and syringes focused on patient comfort, reliability, and ease of use.

Embecta competes directly with large medtech players like Novo Nordisk and Ypsomed in the pen needle space, and faces intense price competition from numerous generic/private-label manufacturers globally. While not direct competitors today, companies advancing automated insulin delivery (e.g., Insulet, Tandem) represent the innovative frontier that could capture future premium market segments.